<DOC>
	<DOCNO>NCT02948829</DOCNO>
	<brief_summary>The purpose study ass cellular immune response follow 2 dos tetravalent dengue vaccine candidate ( TDV ) 4 16 year ' healthy participant .</brief_summary>
	<brief_title>Safety Immunogenicity Takeda 's TDV Healthy Children</brief_title>
	<detailed_description>The vaccine test study TDV . This study look cellular immune response follow TDV vaccination dengue endemic region . The study enroll approximately 200 participant . Participants receive : • TDV 0.5 mL subcutaneous ( SC ) injection All participant receive 2-dose schedule TDV SC injection upper arm Day 1 ( Month 0 ) Day 90 ( Month 3 ) . This multi-center trial conduct Panama Philippines . The overall time participate study approximately 3 year 4 month . Participants make multiple visit clinic contact least every week entire study duration post first injection .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Is age 4 16 year , inclusive ( Latin America ) 4 8 year , inclusive ( Asia ) . 2 . Are good health time entry study determine medical history , physical examination ( include vital sign ) , clinical judgment investigator . 1 . Febrile illness ( body temperature ≥38°C ) moderate severe acute illness infection time enrolment . 2 . History illness , opinion investigator , might interfere result study pose additional risk participant due participation study . 3 . Receipt vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior Day 1 ( Month 0 ) planning receive vaccine within 28 day Day 1 ( Month 0 ) . 4 . Previous participation clinical study dengue candidate vaccine , previous receipt dengue vaccine ( investigational license ) .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>